← Back to CLGN filing summaryOriginal filing text · Part I
Item 11 — Quantitative and Qualitative Disclosures About Market Risk
Collplant Biotechnologies Ltd · 20-F · FY 2025 · Period ended Dec 31, 2025
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
ABOUT MARKET RISK
We are exposed to market risk
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in foreign currency exchange
rates and interest rates.
Foreign Currency
Exchange Risk
Our functional and reporting
currency is the U.S. dollar. Our foreign currency exposures give rise to market risk associated with exchange rate movements of the NIS,
mainly against the U.S. dollar and the Euro. A material portion of our expenses consist principally of payments in NIS made to employees,
subcontractors and consultants for clinical trials, other research and development activities, and purchase of new equipment. A material
portion of our research and development is conducted through collaboration agreements denominated in U.S. dollars, and therefore our net
research and development expenses are subject to significant foreign currency risk. If the NIS fluctuates significantly against either
the U.S. dollar or the Euro, it may have a negative impact on our results of operations.
To date, we have not entered
into any hedging arrangements with respect to foreign currency risk or other derivative financial instruments. In the future, we may enter
into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the operating currencies. These measures,
however, may not adequately protect us from the material adverse effects of such fluctuations.
133
Interest Rate
Risk
At present, our investments
consist primarily of cash and cash equivalents in short-term deposits. The primary objective of our investment activities is to preserve
our capital to fund our operations. Our investments are exposed to market risk due to fluctuation in interest rates, which may affect
our interest income and the fair market value of our investments, if any. We manage this exposure by performing ongoing evaluations of
our investments. Due to the short-term maturities, if any, of our investments to date, their carrying value has always approximated their
fair value. We believe that our exposure to interest rate risk is not significant and a 1% change in market interest rates would not have
a material impact on our assets.